Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Intezyne, Niiki deal

Intezyne acquired Niiki in a stock deal valued at $8.4 million. Intezyne assumes

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE